A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease
← catalyst calendarNCT05956626 · readout in 40 d
Sponsored by Ocugen (industry) · OCGN — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
51estimated
Sites
14
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-25 | actual | When the study began enrolling |
| Primary completion | 2026-09-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Stargardt Disease
Intervention
- Drug: OCU410ST
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in atrophic lesion size as measured by Fundus Auto Fluorescence
measured 12 months (Screening to 12 months post OCU410ST administration)
Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events))
measured 12 months (Screening to 12 months post OCU410ST administration)
Permalink · OCGN's whole pipeline · Catalyst calendar · Every registered study · What changed